Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Oral alendronate can suppress bone turnover but not fracture in kidney transplantation recipients with hyperparathyroidism and chronic kidney disease.

Yamamoto S, Suzuki A, Sasaki H, Sekiguchi-Ueda S, Asano S, Shibata M, Hayakawa N, Hashimoto S, Hoshinaga K, Itoh M.

J Bone Miner Metab. 2013 Jan;31(1):116-22. doi: 10.1007/s00774-012-0391-z. Epub 2012 Oct 18.

PMID:
23076292
2.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8. Epub 2007 Mar 24.

PMID:
17468062
3.

Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.

Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM; Fracture Intervention Research Group.

J Bone Miner Res. 2006 Feb;21(2):292-9. Epub 2005 Oct 31.

4.

Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.

Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.

Menopause. 2013 Jan;20(1):72-8. doi: 10.1097/gme.0b013e31825fe2e8.

PMID:
22968256
5.

Kidney transplantation restored uncoupled bone turnover in end-stage renal disease.

Kawarazaki H, Shibagaki Y, Kido R, Nakajima I, Fuchinoue S, Ando K, Fujita T, Fukagawa M, Teraoka S, Fukumoto S.

Clin Nephrol. 2012 Jul;78(1):10-6.

PMID:
22732332
6.

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Ettinger B, San Martin J, Crans G, Pavo I.

J Bone Miner Res. 2004 May;19(5):745-51. Epub 2004 Jan 19.

7.

Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate.

Olmos JM, Hernández JL, Llorca J, Nan D, Valero C, González-Macías J.

J Clin Endocrinol Metab. 2012 Dec;97(12):4491-7. doi: 10.1210/jc.2012-2999. Epub 2012 Oct 5.

PMID:
23043189
8.

Persistently increased bone turnover and low bone density in long-term survivors to kidney transplantation.

Giannini S, D'Angelo A, Carraro G, Antonello A, Di Landro D, Marchini F, Plebani M, Zaninotto M, Rigotti P, Sartori L, Crepaldi G.

Clin Nephrol. 2001 Nov;56(5):353-63.

PMID:
11758005
9.

Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.

Iizuka T, Matsukawa M.

Climacteric. 2008 Aug;11(4):287-95. doi: 10.1080/13697130801959590.

PMID:
18645694
10.

Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.

Ito H, Ogata H, Yamamoto M, Takahashi K, Shishido K, Takahashi J, Taguchi S, Kinugasa E.

Clin Nephrol. 2009 Jun;71(6):660-8.

PMID:
19473635
11.

Alendronate prevents further bone loss in renal transplant recipients.

Giannini S, D'Angelo A, Carraro G, Nobile M, Rigotti P, Bonfante L, Marchini F, Zaninotto M, Dalle Carbonare L, Sartori L, Crepaldi G.

J Bone Miner Res. 2001 Nov;16(11):2111-7.

12.

Biochemical parameters of bone turnover in kidney transplant recipients.

Smalcelj R, Kusec V, Puretić Z, Mareković Z.

Wien Klin Wochenschr. 1998 May 8;110(9):326-30.

PMID:
9629624
13.
14.

Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.

Lu KC, Tseng CF, Wu CC, Yeung LK, Chen JS, Chao TY, Janckila AJ, Yam LT, Chu P.

Blood Purif. 2006;24(5-6):423-30. Epub 2006 Aug 4.

PMID:
16888370
17.

Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.

Torregrosa JV, Bergua C, Martinez de Osaba MJ, Oppenheimer F, Campistol JM.

Transplant Proc. 2009 Jul-Aug;41(6):2396-8. doi: 10.1016/j.transproceed.2009.06.073.

PMID:
19715931
18.

Effect of cholecalciferol on parathyroid hormone and vitamin D levels in chronic kidney disease.

Basturk T, Unsal A, Ulas T.

Minerva Urol Nefrol. 2011 Dec;63(4):287-92.

PMID:
21996984
19.

Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.

Recker R, Lips P, Felsenberg D, Lippuner K, Benhamou L, Hawkins F, Delmas PD, Rosen C, Emkey R, Salzmann G, He W, Santora AC.

Curr Med Res Opin. 2006 Sep;22(9):1745-55.

PMID:
16968578
20.

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.

Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.

J Bone Miner Res. 2010 Oct;25(10):2239-50. doi: 10.1002/jbmr.119.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk